+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-07-01Number of Pages: 145

Biological Drugs Market (Therapeutic Protein - Levemir, Neulasta, Eylea, Rebif, NovoLog, Enbrel, Avonex, Neupogen, Humalog, Victoza, Lantus, Epogen, Aranesp, and Betaseron; Monoclonal Antibody - Avastin, Rituxan, Lucentis, Humira, Herceptin, and Remicade; Vaccine - Gardasil, Prenvar 13, Fluzone, Cervarix, and Varivax) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Global Biological Drugs Market: Snapshot 

The global market for biological drugs has been demonstrating an upward movement since the last few years. The rising concerns over the increasing cases of side-effects caused by conventional medicines and drugs are having a positive impact on the demand for biological drugs across the world. The trend is expected to remain so over the forthcoming years with the opportunity in the worldwide biological drugs market expanding at a CAGR of 10.10% during the period from 2014 to 2020 and reaching US 287.1 bn by the end of the forecast period. 

Demand for Enbrel to Remain Strong in Future 

Lantus, epogen, avonex, victoza, levemir, betaseron, enbrel, humalog, aranesp, neulasta, novolog, neupogen, rebif, and eylea are some of the main therapeutic proteins used in biological drugs. Enbrel has been witnessing a greater demand than other therapeutic proteins, worldwide. Enbrel is used in the treatment of auto-immune diseases, such as juvenile rheumatoid arthritis, plaque, psoriatic, and psoriasis. The growing prevalence of these diseases has influenced the sales of enbrel. 

Analysts expect the segment to rise at a CAGR of 14.50% over the forecast period. However, the concerns over side-effects of this protein, such as multiple sclerosis, tuberculosis, allergic reactions, and blood related infections, may limit its demand to some extent in the years to come. Lantus and neulasta are the other important therapeutic proteins, which are likely to gain impetus in the global market over the next few years. 

Increasing Investments for Research and Development in Biological Drugs to Ensure North America’s Leadership 

The global market for biological drugs is spread across Europe, North America, Asia Pacific, and the Rest of the World. Thanks to the increased application of biological drugs for the treatment of a number of diseases, such as diabetes, cancer, and other chronic medical conditions, North America has emerged as the leading consumer of biological drugs. Over the forthcoming years, investments to increase research and development activities in biological drugs is likely to heighten, which consequently, is expected to boost the North America biological drugs to a great extent. Expanding at a CAGR of 10.90%, this region will continue to hold the leadership in the global market for biological drugs during the forecast period. 

Europe and Asia Pacific are also projected to gain substantial momentum in their respective markets for biological drugs in the coming years, thanks to the growing awareness among consumers pertaining to the efficiency and other benefits of biological drugs. The unmet medical needs in Asia Pacific is also anticipated to add significantly to the growth of the global biological drugs market in the near future. 

GlaxoSmithKline Plc., Biogen Idec, Novartis AG, Baxter International Inc., Amgen Inc., Merck & Co. Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Pfizer Inc. and Abbott Laboratories are some of the leading manufacturers of biological drugs across the world.

 
The 2013 Biologics Report on pharma.org states that many biopharmaceutical research companies in America are utilizing biological processes to create 907 medicines and vaccines aimed at more than 100 diseases. At present, several biological drugs are in the pipeline for auto-immune diseases, blood diseases, cancer-related conditions, and diabetes and cardiovascular diseases. The global biological drugs market is marked by robust R&D efforts. Companies in the global biological drugs market are investing millions to boost their R&D efforts to create revolutionary medications and therapies to target the most challenging disease.
 
Advancement in biomedical science holds a good promise for the development of novel biological products. This market trend will help the market expand significantly in the foreseeable future. The global biological drugs market is segmented on the basis of monoclonal antibody (mAb), vaccine, therapeutic protein, and geography.
 
The report on the global biological drugs market presents a detailed scenario of the challenges the market faces. The high cost associated with biological drugs will impede the market’s growth. Other factors such as the patent expiration of several blockbuster biological drugs, along with the growing risk of side effects of biological injectable medicines, will also suppress market growth.
 
The research study on the global biological drugs market presents a detailed scenario of the market restraints and delivers valuable recommendations on how players in the market can utilize these challenges to their advantage. A correlation, regression, and time-series analysis has been used to evaluate the key dynamics of the biological drugs industry.
 
Overview of the Global Biological Drugs Market
 
The global biological drugs market is driven by factors such as the growing prevalence of chronic conditions, increasing geriatric population, and accelerating regulatory compliance. In 2014, the global biological drugs market was worth US$161,056.5 million in 2014. With a 10.1% CAGR expected during the forecast period of 2014 to 2020, the global biological drugs market will reach a market value of US$287,139.7 million by 2020.
 
By therapeutic protein, the global biological drugs market is segmented into Enbrel, Neulasta, Lantus, Avonex, Rebif, NovoLog, Eylea, Neupogen, Betaseron, Levemir, Epogen, Aranesp, and Humalog. Enbrel is the dominating therapeutic protein sector in the global biological drugs market.
 
By mAb, the market is divided into Avastin, Rituxan, Remicade, Humira, Herceptin, and Lucentis. According to vaccine, the global biological drugs market is segmented into Ceravix, Varivax, Fluzoone, Gardasil, and Prenvar 13. Humira is the fastest growing mAb sector, while Prevnar 13 is the largest and fastest growing vaccine segment in the global biological drugs market.
 
In terms of geography, the global biological drugs market is divided into RoW, Europe, Asia, and North America. Presently, North America dominates the market, trailed by Europe due to its increasing adoption and use of biological products for the treatment of cancer, diabetes, and other fatal conditions.
 
Companies mentioned in the research report 
 
Some of the leading companies in the global biological drugs market are Roche, Amgen, and Novo Nordisk. Other notable companies in the market are Abbott Laboratories, Pfizer, Novartis, Eli Lilly, Bristol-Myers Squibb, Biogen, and Baxter.
 
Segmentation by therapeutic protein:
  • Levemir
  • Neulasta
  • Eylea
  • Rebif
  • NovoLog
  • Enbrel
  • Avonex
  • Neupogen
  • Humalog
  • Victoza
  • Lantus
  • Epogen
  • Aranesp
  • Betaseron
Segmentation by monoclonal antibody (mAb):
  • Avastin
  • Rituxan
  • Lucentis
  • Humira
  • Herceptin
  • Remicade
Segmentation by vaccine:
  • Gardasil
  • Prenvar 13
  • Fluzone
  • Cervarix
  • Varivax
Major geographies analyzed under this research report are: 
  • Europe
  • North America 
  • Asia-Pacific 
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top